Pharsight

Levulan patents expiration

LEVULAN IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5079262 DUSA Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid
Sep, 2013

(10 years ago)

US5954703 DUSA Method and apparatus for applying 5-aminolevulinic acid
Oct, 2017

(6 years ago)

US8758418 DUSA Illuminator for photodynamic therapy
May, 2018

(6 years ago)

US8216289 DUSA Illuminator for photodynamic therapy
May, 2018

(6 years ago)

US6709446 DUSA Illuminator for photodynamic therapy and diagnosis which produces substantially uniform intensity visible light
May, 2018

(6 years ago)

US7723910 DUSA Method of photodynamically diagnosing or treating a contoured surface
Jun, 2019

(4 years ago)

US11135293 DUSA Methods for photodynamic therapy
Jan, 2038

(13 years from now)

US11690914 DUSA Methods for photodynamic therapy
Jan, 2038

(13 years from now)

US11077192 DUSA Methods for photodynamic therapy
Jan, 2038

(13 years from now)

US10357567 DUSA Methods for photodynamic therapy
Jan, 2038

(13 years from now)

US11571478 DUSA Methods for photodynamic therapy
Jan, 2038

(13 years from now)

Levulan is owned by Dusa.

Levulan contains Aminolevulinic Acid Hydrochloride.

Levulan has a total of 11 drug patents out of which 6 drug patents have expired.

Expired drug patents of Levulan are:

  • US5079262
  • US5954703
  • US8758418
  • US8216289
  • US6709446
  • US7723910

Levulan was authorised for market use on 03 December, 1999.

Levulan is available in solution;topical dosage forms.

Levulan can be used as treatment of actinic keratoses of upper extremities by photodynamic therapy, treatment of non-hyperkeratotic actinic keratoses of face and scalp.

The generics of Levulan are possible to be released after 12 January, 2038.

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-766) Mar 09, 2021
M(M-82) Mar 12, 2013

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using AMINOLEVULINIC ACID HYDROCHLORIDE ingredient

Market Authorisation Date: 03 December, 1999

Treatment: Treatment of non-hyperkeratotic actinic keratoses of face and scalp; Treatment of actinic keratoses of upper extremities by photodynamic therapy

Dosage: SOLUTION;TOPICAL

More Information on Dosage

LEVULAN family patents

Family Patents